Aura Biosciences, Inc. (NASDAQ:AURA) Insider Los Pinos Elisabet De Sells 24,992 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 24,992 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the sale, the insider now directly owns 329,847 shares of the company’s stock, valued at $3,971,357.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Aura Biosciences Trading Up 14.1 %

Aura Biosciences stock opened at $11.74 on Friday. The firm has a 50 day simple moving average of $8.66 and a 200 day simple moving average of $8.06. Aura Biosciences, Inc. has a 1-year low of $5.99 and a 1-year high of $12.38. The firm has a market capitalization of $581.63 million, a price-to-earnings ratio of -6.31 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.04. On average, equities research analysts forecast that Aura Biosciences, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AURA. Scotiabank raised their target price on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research note on Friday. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Finally, HC Wainwright boosted their target price on Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $23.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. boosted its position in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after purchasing an additional 8,194 shares in the last quarter. Levin Capital Strategies L.P. boosted its holdings in Aura Biosciences by 11.2% in the 1st quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock valued at $873,000 after purchasing an additional 11,200 shares during the period. Renaissance Technologies LLC grew its position in shares of Aura Biosciences by 26.3% during the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after purchasing an additional 15,000 shares in the last quarter. Finally, American Century Companies Inc. purchased a new position in shares of Aura Biosciences during the 2nd quarter valued at $119,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.